Anzeige
Mehr »
Montag, 27.04.2026 - Börsentäglich über 12.000 News
Der AI-Boom braucht günstigen Strom - Diese Aktie hat ihn
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
27.04.26 | 17:22
192,56 Euro
-0,79 % -1,54
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
192,16192,4217:44
192,16192,4417:44

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:42Johnson & Johnson: FDA Grants Priority Review For IMAAVY174NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced the FDA has granted Priority Review to the supplemental Biologics License Application for IMAAVY as treatment for people living with...
► Artikel lesen
14:34FDA gewährt J&J-Therapie gegen Anämie beschleunigtes Prüfverfahren5
14:30FDA grants priority review for J&J's warm anemia treatment3
14:18FDA grants priority review to J&J's IMAAVY for rare blood disorder4
14:03Johnson & Johnson: FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)598Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic...
► Artikel lesen
FrJ&J's Xarelto, Invokana to become available through TrumpRx6
FrJohnson & Johnson (JNJ): Growth Engine at a Value Price3
FrJohnson & Johnson to acquire AtraVerse Medical and its transseptal access system1
JOHNSON & JOHNSON Aktie jetzt für 0€ handeln
FrJohnson & Johnson launches head-to-head PFA trial pitting Varipulse against Boston Scientific's Farapulse10
FrJohnson & Johnson to acquire medical device firm Atraverse Medical7
FrJ&J to buy private MedTech Atraverse to boost cardiac ablation portfolio3
FrJ&J's Icotyde approved by US FDA for plaque psoriasis3
DoJNJ set to snap six straight sessions of losses8
MiJ&J's Imaavy demonstrates long-term disease control in myasthenia gravis5
MiJohnson & Johnson: New Data Reinforces Efficacy, Sustained Disease Control Of IMAAVY440NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension in a broad population of antibody-positive adults with...
► Artikel lesen
MiJohnson & Johnson wins CE mark for new Ethicon 4000 surgical stapler3
MiJ&J's Imaavy shows sustained disease control in myasthenia gravis4
MiJohnson & Johnson: IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)697Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+...
► Artikel lesen
MiJohnson & Johnson Announces CE Mark Approval for the New ETHICON 4000 Stapler396Designed to elevate the surgical experience and deliver reliable staple line integrity across a broad range of tissue thickness1 the ETHICON 4000 Surgical Stapler is certified for use in open and...
► Artikel lesen
DiJohnson & Johnson to launch new AI module for EP mapping5
Weiter >>
726 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
5,3,18